Research: T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection
JANUARY 2023: Researchers from SATVI have published results from a study using cutting edge-technology to identify new targets for novel TB vaccine candidates.
The final analysis of a multi-site medical trial involving the University of Cape Town (UCT) has produced the first signal of a potentially effective vaccine against tuberculosis (TB) in almost 100 years.
Phase 3 efficacy study finds shortened 4-month TB drug therapy treatment equivalent to 6-months therapy
The New England Journal of Medicine has published the results of a clinical study which shows that in a randomised phase 3 clinical trial, a shortened 4-month TB treatment was equivalent to the standard 6-month TB treatment.Read more
News from the South African Tuberculosis Vaccine Initiative.
Latest research: γδ T cell antigen receptor polyspecificity enables T cell responses to a broad range of immune challenges
Professor Tom Scriba has co-authored: "γδ T cell antigen receptor polyspecificity enables T cell responses to a broad range of immune challenges" appearing in the Proceedings of the National Academy of Sciences (PNAS).Read more
Professor Tom Scriba has co-authored "BACH 1 promotes tissue necrosis and Mtb susceptibility" appearing in the Nature Microbiology journal.Read more
Professor Tom Scriba to speak at Mini-symposium on TB research Wednesday 7 February 2024 hosted by the IDM, Cape Town
SATVI's Professor Tom Scriba will be presenting a talk on "Activation of endogenous retroelement transcription in tuberculosis" at a Mini-symposium co-hosted by the IDM on Wednesday 7 February 2024.Read more
Study update: Development of the candidate Tuberculosis vaccine H56:IC31 ended based on early data from the Prevention of Recurrence (POR) TB Consortium
The first data analysis from the Phase 2b vaccine trial A-055 show that the H56:IC31 TB vaccine candidate, was well tolerated and demonstrated an immune response compared to the placebo in participants, all of whom had previously had TB.Read more
No vacancies found
On World TB Day, the University of Cape Town (UCT) shines the spotlight on phase three of a clinical trial led by clinicians at the South African Tuberculosis Vaccine Initiative (SATVI).
The corporate history of the South African Tuberculosis Vaccine Initiative is available online. This history is the result of more than 20 interviews conducted over a period of about one year with SATVI staff and students, including ma
The SATVI Annual Report 2022 is available for download.
The University of Cape Town is leading international research into the only licensed TB vaccine, Bacille Calmette-Guerin (BCG), according to a new study.
24 March 2024
(Ends 27 March 2024)More info
Several SATVI researchers will be presenting a wide variety of research papers at the Keystone Tuberculosis: The Host-Pathogen Interface taking place from March 24 to 27 2024.